Dextenza is a medication used to treat ocular pain and inflammation after ophthalmic surgery, particularly cataract surgery. It comes as a preservative-free, intracanalicular insert. Patients place it in the lower lacrimal punctum, the natural opening in the eyelid, and into the canaliculus. As a result, the device dissolves over time, eliminating the need for frequent eye drops or injections.
The medication contains a corticosteroid that reduces inflammation and alleviates pain. Specifically, a small, bioresorbable implant holds the drug. It then gradually releases the drug over up to 30 days. This ensures continuous relief from postoperative symptoms.
Moreover, the U.S. Food and Drug Administration (FDA) has approved Dextenza for managing postoperative inflammation and pain after cataract surgery. As a result, patients prefer this treatment because it is more convenient than traditional methods like eye drops.
However, although Dextenza provides many benefits, it may cause side effects. For example, some patients may experience irritation or discomfort at the insertion site. Others may have increased intraocular pressure. Therefore, healthcare providers should supervise its use and monitor for any adverse reactions. Additionally, patients should attend regular follow-up appointments to assess the medication’s effectiveness and maintain eye health.
